Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guarneri

Showing results (1271-1280 of 1,433) with videos related to

Pageof 144
Sort By:
Advanced Materials (Deerfield Beach, Fla.)|August 6, 2021
Metavalent Bonding in Crystalline Solids: How Does It Collapse?Ludovica Guarneri, Stefan Jakobs, Alexander von Hoegen, et al.
Clinical Lung Cancer|June 17, 2026
CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural MesotheliomaGiulia Pasello, Daniela Scattolin, Eleonora Faccioli, et al.
ESMO Open|December 20, 2024
Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept studyF Miglietta, A Collesei, C Vernieri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2019
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR<sup>+</sup>/HER2<sup>-</sup> Breast CancerSara A Hurvitz, Miguel Martin, Michael F Press, et al.
Ebiomedicine|November 14, 2022
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trialValentina Guarneri, Fara Bras-Maristany, Maria Vittoria Dieci, et al.
JAMA Oncology|February 13, 2025
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical TrialMaria Vittoria Dieci, Giancarlo Bisagni, Stefania Bartolini, et al.
Journal of Translational Medicine|March 5, 2024
Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patientsGiulia Pasello, Aline S C Fabricio, Paola Del Bianco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2023
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast CancerFederica Miglietta, Moira Ragazzi, Bethania Fernandes, et al.
Eclinicalmedicine|September 2, 2025
Supplemental parenteral nutrition within an enhanced recovery program for open pancreatoduodenectomy for cancer: a pragmatic, multicenter, randomized controlled trialLuca Gianotti, Salvatore Paiella, Giovanni Capretti, et al.
NPJ Breast Cancer|February 20, 2025
Temporal evolution of breast cancer brain metastases treatments and outcomesMichele Bottosso, Gaia Griguolo, Severine Guiu, et al.
Pageof 144

Showing results (1271-1280 of 1,433) with videos related to

Sort By:
Pageof 144
Advanced Materials (Deerfield Beach, Fla.)|August 6, 2021
Metavalent Bonding in Crystalline Solids: How Does It Collapse?Ludovica Guarneri, Stefan Jakobs, Alexander von Hoegen, et al.
Clinical Lung Cancer|June 17, 2026
CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural MesotheliomaGiulia Pasello, Daniela Scattolin, Eleonora Faccioli, et al.
ESMO Open|December 20, 2024
Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept studyF Miglietta, A Collesei, C Vernieri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2019
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR<sup>+</sup>/HER2<sup>-</sup> Breast CancerSara A Hurvitz, Miguel Martin, Michael F Press, et al.
Ebiomedicine|November 14, 2022
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trialValentina Guarneri, Fara Bras-Maristany, Maria Vittoria Dieci, et al.
JAMA Oncology|February 13, 2025
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical TrialMaria Vittoria Dieci, Giancarlo Bisagni, Stefania Bartolini, et al.
Journal of Translational Medicine|March 5, 2024
Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patientsGiulia Pasello, Aline S C Fabricio, Paola Del Bianco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2023
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast CancerFederica Miglietta, Moira Ragazzi, Bethania Fernandes, et al.
Eclinicalmedicine|September 2, 2025
Supplemental parenteral nutrition within an enhanced recovery program for open pancreatoduodenectomy for cancer: a pragmatic, multicenter, randomized controlled trialLuca Gianotti, Salvatore Paiella, Giovanni Capretti, et al.
NPJ Breast Cancer|February 20, 2025
Temporal evolution of breast cancer brain metastases treatments and outcomesMichele Bottosso, Gaia Griguolo, Severine Guiu, et al.
Pageof 144